PLoS ONE · 2018 · 12 citations · 52 references
Life SciencesImmunologyMicrobiologyAdaptive ImmunityHost-pathogen InteractionsMicrobial PathogenesisAntibody-mediated ProtectionAntigenic VariationBacterial ImmunologyBacterial PathogenesisBacterial SerologyPathogen RecognitionActinobacillus PleuropneumoniaActinobacillus Pleuropneumoniae InfectionBacterial Immune ResponsesCross-protective ImmunityIndirect Enzyme-linked Immunosorbent AssayProtectionProtective Antigen IdentificationRecombinant Fusion Proteins
GALT is an important antigen of Actinobacillus pleuropneumoniae (APP), which was shown to provide partial protection against APP infection in a previous study in our lab. The main purpose of the present study is to investigate GALT induced cross-protection between different APP serotypes and elucidate key mechanisms of the immune response to GALT antigenic stimulation. Bioinformatic analysis demonstrated that galT is a highly conserved gene in APP, widely distributed across multiple pathogenic strains. Homologies between any two strains ranges from 78.9% to 100% regarding the galT locus. Indirect enzyme-linked immunosorbent assay (ELISA) confirmed that GALT specific antibodies could not be induced by inactivated APP L20 or MS71 whole cell bacterin preparations. A recombinant fusion GALT protein derived from APP L20, however has proven to be an effective cross-protective antigen against APP sevorar 1 MS71 (50%, 4/8) and APP sevorar 5b L20 (75%, 6/8). Histopathological examinations have confirmed that recombinant GALT vaccinated animals showed less severe pathological signs in lung tissues than negative controls after APP challenge. Immunohistochemical (IHC) analysis indicated that the infiltration of neutrophils in the negative group is significantly increased compared with that in the normal control (P<0.001) and that in surviving animals is decreased compared to the negative group. Anti-GALT antibodies were shown to mediate phagocytosis of neutrophils. After interaction with anti-GALT antibodies, survival rate of APP challenged vaccinated animals was significantly reduced (P<0.001). This study demonstrated that GALT is an effective cross-protective antigen, which could be used as a potential vaccine candidate against multiple APP serotypes.
52
Allison L. Totura, Alan C. Whitmore, Sudhakar Agnihothram et al. · mBio · 2015 · 465 citations · Full text
Farid El Garch, Anno de Jong, Shabbir Simjee et al. · Veterinary Microbiology · 2016 · 143 citations
Veterinary Medicine, Infectious Diseases, Veterinary Microbiology +17
An O Antigen Capsule Modulates Bacterial Pathogenesis in Shigella sonnei
Mariaelena Caboni, Thierry Pédron, Omar Rossi et al. · PLoS Pathogens · 2015 · 123 citations · Full text